Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. [electronic resource]
Producer: 20160427Description: e0133219 p. digitalISSN:- 1932-6203
- Antineoplastic Agents -- pharmacology
- Cell Line, Tumor
- Class I Phosphatidylinositol 3-Kinases
- Diamines -- pharmacology
- Drug Resistance, Neoplasm -- genetics
- Epithelial Cells -- drug effects
- Female
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Humans
- Lapatinib
- Mammary Glands, Human
- Mutation
- Oxadiazoles -- pharmacology
- Phosphatidylinositol 3-Kinases -- genetics
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- Pyrazoles -- pharmacology
- Quinazolines -- pharmacology
- Receptor, ErbB-2 -- antagonists & inhibitors
- Ribosomal Protein S6 -- genetics
- Signal Transduction
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.